These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
344 related articles for article (PubMed ID: 11586021)
21. Desmoglein 1 and 3 enzyme-linked immunosorbent assay in Iranian patients with pemphigus vulgaris: correlation with phenotype, severity, and disease activity. Daneshpazhooh M; Chams-Davatchi C; Khamesipour A; Mansoori P; Taheri A; Firooz A; Mortazavi H; Esmaili N; Dowlati Y J Eur Acad Dermatol Venereol; 2007 Nov; 21(10):1319-24. PubMed ID: 17958835 [TBL] [Abstract][Full Text] [Related]
22. Case of pemphigus foliaceus that shifted into pemphigus vulgaris after adrenal tumor resection. Awazawa R; Yamamoto Y; Gushi M; Taira K; Yagi N; Asato Y; Hagiwara K; Uezato H J Dermatol; 2007 Aug; 34(8):549-55. PubMed ID: 17683386 [TBL] [Abstract][Full Text] [Related]
23. Prolonged clinical remission of patients with severe pemphigus upon rapid removal of desmoglein-reactive autoantibodies by immunoadsorption. Eming R; Rech J; Barth S; Kalden JR; Schuler G; Harrer T; Hertl M Dermatology; 2006; 212(2):177-87. PubMed ID: 16484825 [TBL] [Abstract][Full Text] [Related]
24. IgG-induced clustering of desmogleins 1 and 3 in skin of patients with pemphigus fits with the desmoglein nonassembly depletion hypothesis. Oktarina DA; van der Wier G; Diercks GF; Jonkman MF; Pas HH Br J Dermatol; 2011 Sep; 165(3):552-62. PubMed ID: 21692763 [TBL] [Abstract][Full Text] [Related]
25. Anti-desmoglein IgG autoantibodies in patients with pemphigus in remission. Kwon EJ; Yamagami J; Nishikawa T; Amagai M J Eur Acad Dermatol Venereol; 2008 Sep; 22(9):1070-5. PubMed ID: 18410336 [TBL] [Abstract][Full Text] [Related]
26. Influence of intravenous immunoglobulin therapy on autoantibody titers to desmoglein 3 and desmoglein 1 in pemphigus vulgaris. Sami N; Bhol KC; Ahmed RA Eur J Dermatol; 2003; 13(4):377-81. PubMed ID: 12948919 [TBL] [Abstract][Full Text] [Related]
27. Development of pemphigus vulgaris in a patient with pemphigus foliaceus: antidesmoglein antibody profile shift confirmed by enzyme-linked immunosorbent assay. Ishii K; Amagai M; Ohata Y; Shimizu H; Hashimoto T; Ohya K; Nishikawa T J Am Acad Dermatol; 2000 May; 42(5 Pt 2):859-61. PubMed ID: 10767686 [TBL] [Abstract][Full Text] [Related]
28. [Transition from pemphigus vulgaris to pemphigus foliaceus: a case report]. Lévy-Sitbon C; Reguiaï Z; Durlach A; Goeldel AL; Grange F; Bernard P Ann Dermatol Venereol; 2013 Dec; 140(12):788-92. PubMed ID: 24315225 [TBL] [Abstract][Full Text] [Related]
29. Early detection and successful management of oral pemphigus vulgaris: a case report. Endo H; Rees TD; Matsue M; Kuyama K; Nakadai M; Yamamoto H J Periodontol; 2005 Jan; 76(1):154-60. PubMed ID: 15830652 [TBL] [Abstract][Full Text] [Related]
30. Four mild but refractory cases of pemphigus foliaceus successfully treated with intravenous immunoglobulin. Kawakami T; Koga H; Saruta H; Ueda A; Inoue Y; Soma Y; Ishii N; Hashimoto T J Dermatol; 2013 Nov; 40(11):869-73. PubMed ID: 24127870 [TBL] [Abstract][Full Text] [Related]
31. Locations of acantholysis in pemphigus vulgaris and pemphigus foliaceus. Ohata C; Ishii N; Furumura M J Cutan Pathol; 2014 Nov; 41(11):880-9. PubMed ID: 25265985 [TBL] [Abstract][Full Text] [Related]
32. Neonatal pemphigus vulgaris with extensive mucocutaneous lesions from a mother with oral pemphigus vulgaris. Campo-Voegeli A; Muñiz F; Mascaró JM; García F; Casals M; Arimany JL; Amagai M; Camps A Br J Dermatol; 2002 Oct; 147(4):801-5. PubMed ID: 12366435 [TBL] [Abstract][Full Text] [Related]
33. [Prolonged complete clinical remission in patients with severe pemphigus vulgaris after cycles of intravenous cyclophosphamide]. España Alonso A; Panizo C; Fernández S; Marquina M; Pretel M; Aguado L; Sánchez-Ibarrola A Actas Dermosifiliogr; 2009 Mar; 100(2):113-20. PubMed ID: 19445875 [TBL] [Abstract][Full Text] [Related]
34. Orodigital pemphigus vulgaris: a pathogenic role of anti-desmoglein-3 autoantibodies in pemphigus paronychia? Laffitte E; Panizzon RG; Borradori L Dermatology; 2008; 217(4):337-9. PubMed ID: 18799879 [TBL] [Abstract][Full Text] [Related]
35. Antibodies to the amino-terminal domain of desmoglein 1 are retained during transition from pemphigus vulgaris to pemphigus foliaceus. España A; Koga H; Suárez-Fernández R; Ohata C; Ishii N; Irarrazaval I; Teye K; Ohyama B; Hashimoto T Eur J Dermatol; 2014; 24(2):174-9. PubMed ID: 24776707 [TBL] [Abstract][Full Text] [Related]
36. Disease progression from mucosal to mucocutaneous involvement in a patient with desquamative gingivitis associated with pemphigus vulgaris. Endo H; Rees TD; Hallmon WW; Kuyama K; Nakadai M; Kato T; Kono Y; Yamamoto H J Periodontol; 2008 Feb; 79(2):369-75. PubMed ID: 18251653 [TBL] [Abstract][Full Text] [Related]
37. Pemphigus vulgaris: recent advances in our understanding of its pathogenesis. Femiano F Minerva Stomatol; 2007 Apr; 56(4):215-23. PubMed ID: 17452959 [TBL] [Abstract][Full Text] [Related]
38. Clinical and immunological profile of umbilical involvement in pemphigus vulgaris and pemphigus foliaceus. Oliveira Júnior JV; Maruta CW; Sousa JX; Santi CG; Valente NY; Ichimura LM; Périgo AM; Aoki V Clin Exp Dermatol; 2013 Jan; 38(1):20-4. PubMed ID: 23083306 [TBL] [Abstract][Full Text] [Related]
39. Three cases of transition from pemphigus vulgaris to pemphigus foliaceus confirmed by desmoglein ELISA. Ng PP; Thng ST Dermatology; 2005; 210(4):319-21. PubMed ID: 15942219 [TBL] [Abstract][Full Text] [Related]